Technical challenges and limitations of current mouse models of ovarian cancer

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Garson, Kenneth ^a   Gamwell, Lisa F ^a,b   Pitre, Elizabeth M G ^a,b   Vanderhyden, Barbara C ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Genetically engineered; Mouse models; Ovarian cancer; Ovarian surface epithelium; Ovary; Oviduct

Indexed keywords

ADENOVIRUS VECTOR; CRE RECOMBINASE;

CANCER INHIBITION; CELL POPULATION; CELL TYPE; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VARIABILITY; MOUSE; NONHUMAN; ONTOGENY; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SECRETORY CELL; TRANSGENE;

EID: 84870065741     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-39     Document Type: Review

References (98)

1. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Connolly DC, Hensley HH, Curr Protoc Pharmacol 2009 45 14 12 11 14 12 26
2. Ovarian cancer mouse models: a summary of current models and their limitations. Fong MY, Kakar SS, J Ovarian Res 2009 2 12 10.1186/1757-2215-2-12 19781107
3. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Lu KH, Yates MS, Mok SC, Cancer Prev Res (Phila) 2009 2 773 775 10.1158/1940-6207.CAPR-09-0156
4. Genetically engineered mouse models of ovarian cancer and their utility in drug discovery. Sale S, Curr Protoc Pharmacol 2009 Chapter 14 Unit 14 11 22294391
5. Evaluating the progenitor cells of ovarian cancer: analysis of current animal models. King SM, Burdette JE, BMB Rep 2011 44 435 445 10.5483/BMBRep.2011.44.7.435 21777513
6. Minireview: animal models and mechanisms of ovarian cancer development. Mullany LK, Richards JS, Endocrinology 2012 153 1585 1592 10.1210/en.2011-2121 22396450
7. Epithelial ovarian cancer: focus on genetics and animal models. Shan W, Liu J, Cell Cycle 2009 8 731 735 10.4161/cc.8.5.7848 19221485
8. Models of ovarian cancer-are we there yet? Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC, Mol Cell Endocrinol 2005 239 15 26 10.1016/j.mce.2005. 03.019 15955618
9. Mouse models of cancer. Cheon DJ, Orsulic S, Annu Rev Pathol 2011 6 95 119 10.1146/annurev.pathol.3.121806.154244 20936938
10. Origins and molecular pathology of ovarian cancer. Bell DA, Mod Pathol 2005 18 Suppl 2 19 32 15761464
11. Early de novo ovarian carcinoma. A study of fourteen cases. Bell DA, Scully RE, Cancer 1994 73 1859 1864 10.1002/1097-0142(19940401)73:7<1859:: AID-CNCR2820730714>3.0.CO;2-L 8137211
12. Genetic analysis of the early natural history of epithelial ovarian carcinoma. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, et al. PLoS One 2010 5 10358 10.1371/journal.pone.0010358 20436685
13. The origin of ovarian carcinomas: a developmental view. Auersperg N, Woo MM, Gilks CB, Gynecol Oncol 2008 110 452 454 10.1016/j.ygyno.2008.05.031 18603285
14. Precursor lesions of ovarian epithelial malignancy. Feeley KM, Wells M, Histopathology 2001 38 87 95 10.1046/j.1365-2559.2001.01042.x 11207821
15. The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts. Gendronneau G, Boucherat O, Aubin J, Lemieux M, Jeannotte L, Endocrinology 2012 153 1484 1497 10.1210/en.2011-1766 22315454
16. Ovarian epithelial inclusion cysts in chronically superovulated CD1 and Smad2 dominant-negative mice. Burdette JE, Oliver RM, Ulyanov V, Kilen SM, Mayo KE, Woodruff TK, Endocrinology 2007 148 3595 3604 10.1210/en.2007-0030 17431007
17. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Cheng W, Liu J, Yoshida H, Rosen D, Naora H, Nat Med 2005 11 531 537 10.1038/nm1230 15821746
18. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Dubeau L, Gynecol Oncol 1999 72 437 442 10.1006/gyno.1998.5275 10053122
19. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH, J Pathol 2001 195 451 456 10.1002/path.1000 11745677
20. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B, Int J Gynecol Pathol 2004 23 35 40 10.1097/01.pgp.0000101082. 35393.84 14668548
21. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al. J Pathol 2007 211 26 35 10.1002/path.2091 17117391
22. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP, J Clin Oncol 2008 26 4160 4165 10.1200/JCO.2008.16.4814 18757330
23. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP, Gynecol Oncol 2008 109 168 173 10.1016/j.ygyno.2008.01.012 18342932
24. Serous carcinogenesis in the fallopian tube: a descriptive classification. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP, Int J Gynecol Pathol 2008 27 1 9 10.1097/pgp.0b013e31814b191f 18156967
25. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Crum CP, McKeon FD, Xian W, Int J Gynecol Cancer 2012 22 Suppl 1 29 34 22543918
26. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Roh MH, Kindelberger D, Crum CP, Am J Surg Pathol 2009 33 376 383 10.1097/PAS.0b013e3181868904 19011565
27. Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D, Huang J, Witte ON, Memarzadeh S, Stem Cells 2012 30 2487 2497 10.1002/stem.1207 22911892
28. The Mouse Ovarian Surface Epithelium Contains a Population of LY6A (SCA-1) Expressing Progenitor Cells That Are Regulated by Ovulation-Associated Factors. Gamwell LF, Collins O, Vanderhyden BC, Biol Reprod 2012 87 80 10.1095/biolreprod.112.100347 22914315
29. Ovarian surface epithelium in patients with severe ovarian infertility: a potential source of cells expressing markers of pluripotent/multipotent stem cells. Virant-Klun I, Skutella T, Stimpfel M, Sinkovec J, J Biomed Biotechnol 2011 2011 381928 22187524
30. Chang HL, MacLaughlin DT, Donahoe PK, Somatic stem cells of the ovary and their relationship to human ovarian cancers Cambridge (MA): StemBook 2008
31. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, Dombkowski D, Preffer F, Cohen KS, Teixeira J, Donahoe PK, Proc Natl Acad Sci U S A 2008 105 12469 12473 10.1073/pnas.0805012105 18711140
32. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Motohara T, Masuko S, Ishimoto T, Yae T, Onishi N, Muraguchi T, Hirao A, Matsuzaki Y, Tashiro H, Katabuchi H, et al. Carcinogenesis 2011 32 1597 1606 10.1093/carcin/bgr183 21828057
33. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC, Cancer Res 2003 63 1389 1397 12649204
34. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA, Endocrinology 1995 136 4951 4962 10.1210/en.136.11.4951 7588229
35. A mesenchymal perspective of Mullerian duct differentiation and regression in Amhr2-lacZ mice. Arango NA, Kobayashi A, Wang Y, Jamin SP, Lee HH, Orvis GD, Behringer RR, Mol Reprod Dev 2008 75 1154 1162 10.1002/mrd.20858 18213646
36. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Kananen K, Markkula M, Rainio E, Su JG, Hsueh AJ, Huhtaniemi IT, Mol Endocrinol 1995 9 616 627 10.1210/me.9.5.616 7565808
37. Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. Garson K, Macdonald E, Dube M, Bao R, Hamilton TC, Vanderhyden BC, J Soc Gynecol Investig 2003 10 244 250 10.1016/S1071-5576(03)00073-X 12759154
38. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Dutertre M, Gouedard L, Xavier F, Long WQ, di Clemente N, Picard JY, Rey R, Endocrinology 2001 142 4040 4046 10.1210/en.142.9.4040 11517183
39. Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Miyoshi I, Takahashi K, Kon Y, Okamura T, Mototani Y, Araki Y, Kasai N, Mol Reprod Dev 2002 63 168 176 10.1002/mrd.10175 12203826
40. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Woo MM, Gilks CB, Verhage HG, Longacre TA, Leung PC, Auersperg N, Gynecol Oncol 2004 93 315 319 10.1016/j.ygyno.2004.01.047 15099939
41. Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB, Auersperg N, Clin Cancer Res 2004 10 7958 7964 10.1158/1078-0432.CCR-04-1261 15585630
42. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. Liang S, Yang N, Pan Y, Deng S, Lin X, Yang X, Katsaros D, Roby KF, Hamilton TC, Connolly DC, et al. PLoS One 2009 4 4295 10.1371/journal.pone.0004295 19172191
43. The development of a mouse model of ovarian endosalpingiosis. Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Woodruff TK, Endocrinology 2005 146 5228 5236 10.1210/en.2005-0697 16141389
44. Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Yang DH, Fazili Z, Smith ER, Cai KQ, Klein-Szanto A, Cohen C, Horowitz IR, Xu XX, Am J Pathol 2006 169 258 267 10.2353/ajpath.2006.060036 16816378
45. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, Pike MC, Shuler CF, Maxson R, Dubeau L, Curr Biol 2005 15 561 565 10.1016/j.cub.2005.01.052 15797026
46. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R, Oncogene 2005 24 8343 8348 10.1038/sj.onc.1208985 16170371
47. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L, Cancer Res 2010 70 221 228 10.1158/0008-5472.CAN-09-3232 20028858
48. Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility. Tanaka Y, Park JH, Tanwar PS, Kaneko-Tarui T, Mittal S, Lee HJ, Teixeira JM, Endocrinology 2012 153 404 416 10.1210/en.2011-1191 22128018
49. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Tanwar PS, Lee HJ, Zhang L, Zukerberg LR, Taketo MM, Rueda BR, Teixeira JM, Biol Reprod 2009 81 545 552 10.1095/biolreprod.108.075648 19403928
50. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR, Nat Genet 2002 32 408 410 10.1038/ng1003 12368913
51. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ, Richards JS, Cancer Res 2009 69 6463 6472 10.1158/0008-5472.CAN-08-3363 19679546
52. Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Fan HY, Liu Z, Cahill N, Richards JS, Mol Endocrinol 2008 22 2128 2140 10.1210/me.2008-0095 18606860
53. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Lague MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Dore M, et al. Carcinogenesis 2008 29 2062 2072 10.1093/carcin/ bgn186 18687666
54. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Mullany LK, Liu Z, King ER, Wong KK, Richards JS, Endocrinology 2012 153 1638 1648 10.1210/en.2011-2131 22396451
55. Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes. Daikoku T, Jackson L, Besnard V, Whitsett J, Ellenson LH, Dey SK, Gynecol Oncol 2011 122 424 429 10.1016/j.ygyno.2011.04.022 21570712
56. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/beta-catenin and PTEN. Tanwar PS, Zhang L, Kaneko-Tarui T, Curley MD, Taketo MM, Rani P, Roberts DJ, Teixeira JM, PLoS One 2011 6 20715 10.1371/journal.pone.0020715 21695255
57. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Richards JS, Fan HY, Liu Z, Tsoi M, Lague MN, Boyer A, Boerboom D, Oncogene 2012 31 1504 1520 10.1038/onc.2011.341 21860425
58. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM, Proc Natl Acad Sci U S A 2012 109 3921 3926 10.1073/pnas.1117135109 22331912
59. Dicer is required for female reproductive tract development and fertility in the mouse. Gonzalez G, Behringer RR, Mol Reprod Dev 2009 76 678 688 10.1002/mrd.21010 19197916
60. The regulatory role of Dicer in folliculogenesis in mice. Lei L, Jin S, Gonzalez G, Behringer RR, Woodruff TK, Mol Cell Endocrinol 2010 315 63 73 10.1016/j.mce.2009.09.021 19799966
61. Stromal Liver Kinase B1 [STK11] Signaling Loss Induces Oviductal Adenomas and Endometrial Cancer by Activating Mammalian Target of Rapamycin Complex 1. Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM, PLoS Genet 2012 8 1002906 10.1371/journal.pgen.1002906 22916036
62. Foxg1 haploinsufficiency reduces the population of cortical intermediate progenitor cells: effect of increased p21 expression. Siegenthaler JA, Tremper-Wells BA, Miller MW, Cereb Cortex 2008 18 1865 1875 10.1093/cercor/ bhm209 18065723
63. A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. MacLean HE, Chiu WS, Ma C, McManus JF, Davey RA, Cameron R, Notini AJ, Zajac JD, Physiol Genomics 2008 33 133 137 10.1152/physiolgenomics. 00260.2007 18171720
64. Deletion of the orphan nuclear receptor COUP-TFII in uterus leads to placental deficiency. Petit FG, Jamin SP, Kurihara I, Behringer RR, DeMayo FJ, Tsai MJ, Tsai SY, Proc Natl Acad Sci U S A 2007 104 6293 6298 10.1073/pnas.0702039104 17404209
65. RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L, J Biol Chem 2006 281 2649 2653 16326700
66. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY, Cancer Res 2003 63 3459 3463 12839925
67. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC, PLoS One 2009 4 8534 10.1371/journal.pone.0008534 20046869
68. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC, PLoS One 2009 4 8404 10.1371/journal.pone.0008404 20046879
69. A role for BRCA1 in uterine leiomyosarcoma. Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, et al. Cancer Res 2009 69 8231 8235 10.1158/0008-5472.CAN-09-2543 19843854
70. Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, et al. Cancer Res 2012 72 4141 4153 10.1158/0008-5472.CAN-11-3834 22617326
71. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H, Genes Dev 2004 18 2952 2962 10.1101/gad.322004 15574596
72. Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Saenz Robles MT, Symonds H, Chen J, Van Dyke T, Mol Cell Biol 1994 14 2686 2698 10.1128/MCB.14.4.2686 8139568
73. Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Stubdal H, Zalvide J, Campbell KS, Schweitzer C, Roberts TM, DeCaprio JA, Mol Cell Biol 1997 17 4979 4990 9271376
74. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC, Endocrinology 2010 151 929 938 10.1210/en.2009-0602 20056833
75. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Ahuja D, Saenz-Robles MT, Pipas JM, Oncogene 2005 24 7729 7745 10.1038/sj.onc.1209046 16299533
76. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T, Nat Med 2005 11 63 70 10.1038/nm1173 15619626
77. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA, Mol Cancer Ther 2011 10 1440 1449 10.1158/1535-7163.MCT-11-0240 21632463
78. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, et al. J Exp Med 2012 209 495 506 10.1084/jem.20111413 22351930
79. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, et al. J Clin Invest 2012 122 553 557 10.1172/JCI59309 22214849
80. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, et al. Cancer Cell 2007 11 321 333 10.1016/j.ccr.2007.02.016 17418409
81. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR, Clin Cancer Res 2011 17 7359 7372 10.1158/1078-0432.CCR-11-1388 21903772
82. Formation and barrier function of tight junctions in human ovarian surface epithelium. Zhu Y, Maric J, Nilsson M, Brannstrom M, Janson PO, Sundfeldt K, Biol Reprod 2004 71 53 59 10.1095/biolreprod.103.022913 14973266
83. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW, Science 1997 275 1320 1323 10.1126/science.275.5304.1320 9036860
84. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR, Cell 1993 73 309 319 10.1016/0092-8674(93)90231-E 8477447
85. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM, Proc Natl Acad Sci U S A 2001 98 15191 15196 10.1073/pnas. 261452898 11734628
86. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA, Fang B, Clin Cancer Res 1999 5 4208 4213 10632362
87. Isoform-specific regulation and localization of the coxsackie and adenovirus receptor in human airway epithelia. Excoffon KJ, Gansemer ND, Mobily ME, Karp PH, Parekh KR, Zabner J, PLoS One 2010 5 9909 10.1371/journal.pone. 0009909 20361046
88. Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells. Lutschg V, Boucke K, Hemmi S, Greber UF, Nat Commun 2011 2 391 21750545
89. Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells. Johansson C, Jonsson M, Marttila M, Persson D, Fan XL, Skog J, Frangsmyr L, Wadell G, Arnberg N, J Virol 2007 81 954 963 10.1128/JVI.01995-06 17079302
90. Interleukin-8 expression and modulation in human preovulatory follicles and ovarian cells. Arici A, Oral E, Bukulmez O, Buradagunta S, Engin O, Olive DL, Endocrinology 1996 137 3762 3769 10.1210/en.137.9.3762 8756544
91. Interleukin-8 in the human fallopian tube. Palter SF, Mulayim N, Senturk L, Arici A, J Clin Endocrinol Metab 2001 86 2660 2667 10.1210/jc.86.6.2660 11397869
92. Differential expression and estrogen response of lactoferrin gene in the female reproductive tract of mouse, rat, and hamster. Teng CT, Beard C, Gladwell W, Biol Reprod 2002 67 1439 1449 10.1095/biolreprod.101.002089 12390874
93. High concentrations of lactoferrin in the follicular fluid correlate with embryo quality during in vitro fertilization cycles. Yanaihara A, Mitsukawa K, Iwasaki S, Otsuki K, Kawamura T, Okai T, Fertil Steril 2007 87 279 282 10.1016/j.fertnstert.2006.06.025 17094987
94. Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model. Saito F, Tashiro H, To Y, Ohtake H, Ohba T, Suzuki A, Katabuchi H, Int J Gynecol Cancer 2011 21 1343 1349 10.1097/IGC. 0b013e31822d2a8a 21989218
95. Mouse models of cancer: does the strain matter? Hunter KW, Nat Rev Cancer 2012 12 144 149 22257951
96. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, et al. Nat Genet 2004 36 1133 1137 10.1038/ng1104-1133 15514660
97. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, Ried T, Oncogene 2002 21 5097 5107 10.1038/sj.onc.1205636 12140760
98. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Laviolette LA, Ethier JF, Senterman MK, Devine PJ, Vanderhyden BC, Menopause 2011 18 549 557 10.1097/gme.0b013e3181fca1b6 21221022